Shanghai Henlius Biotech Competitors and Similar CompaniesClear all
Shanghai Henlius Biotech's competitors and similar companies include Anavex, Tetherex, Medivir and Ayala Pharmaceuticals.
 Shanghai Henlius Biotech Shanghai Henlius Biotech provides clinical-stage biopharmaceutical services.
|  Anavex Anavex is a biopharmaceutical company developing drugs for the treatment of cancer and neurological diseases. |  Tetherex Tetherex Pharmaceuticals Corp is a biopharmaceutical company focused on development of therapeutics for the treatment of inflammation, thrombosis and tumor metastasis across a broad range of severe diseases. |  Medivir Medivir is a company that researches, develops, and sells pharmaceuticals primarily for the treatment of oncology. |  Ayala Pharmaceuticals Ayala Pharmaceuticals is a clinical-stage biopharmaceutical company developing medicines for cancers that are genetically defined. | |
Founding Date | Founding Date 2009 | Founding Date 2006 | Founding Date 2014 | Founding Date 1988 | Founding Date 2017 |
Type | Type Private | Type Public | Type Private | Type Public | Type Public |
Tags | |||||
Locations | Locations HQ | Locations New York, US HQ Reno, US | Locations Oklahoma City, US HQ Morrisville, US | Locations Huddinge, SE HQ | Locations Wilmington, US HQ Rehovot, IL Wilmington, US |
Employees | Employees 1273% increase | Employees 1623% increase | Employees N/A | Employees 9 | Employees 29 |
Valuation ($) | Valuation ($) N/A | Valuation ($) 484.6 m | Valuation ($) N/A | Valuation ($) 39.2 m | Valuation ($) 7.4 m |
Financial | |||||
Revenue (est.) | Revenue (est.) N/A | Revenue (est.) N/A | Revenue (est.) N/A | Revenue (est.) kr8.5m (FY, 2025) | Revenue (est.) $692k (FY, 2022) |
Cost of goods | Cost of goods N/A | Cost of goods N/A | Cost of goods N/A | Cost of goods N/A | Cost of goods $602k (FY, 2022) |
Gross profit | Gross profit N/A | Gross profit N/A | Gross profit N/A | Gross profit kr8.5m (FY, 2025) | Gross profit $90k (FY, 2022) |
Net income | Net income N/A | Net income ($46.4m) (FY, 2025) | Net income N/A | Net income (kr94.4m) (FY, 2025) | Net income ($38m) (FY, 2022) |
Funding | |||||
Latest funding round | Latest funding round $ 156m (almost 8 years ago) | Latest funding round N/A | Latest funding round $ 43m (about 8 years ago) | Latest funding round N/A | Latest funding round N/A |
Total funding raised | Total funding raised $ 346m | Total funding raised $ 12.6m | Total funding raised $ 46.2m | Total funding raised N/A | Total funding raised $ 47m |
For sources of this data, please see the company profile
View Company Profiles
Anavex
HQ
New York, US
Employees
16↑ 23% increase
Anavex is a biopharmaceutical company developing drugs for the treatment of cancer and neurological diseases.
View companyTetherex
HQ
Oklahoma City, US
Tetherex Pharmaceuticals Corp is a biopharmaceutical company focused on development of therapeutics for the treatment of inflammation, thrombosis and tumor metastasis across a broad range of severe diseases.
View companyMedivir
HQ
Huddinge, SE
Employees
9
Medivir is a company that researches, develops, and sells pharmaceuticals primarily for the treatment of oncology.
View companyAyala Pharmaceuticals
HQ
Wilmington, US
Employees
29
Ayala Pharmaceuticals is a clinical-stage biopharmaceutical company developing medicines for cancers that are genetically defined.
View company